Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Mar-Apr;62(2):193-7.
doi: 10.18097/PBMC20166202193.

[The effect of antioxidants on in vivo and in vitro methemoglobin formation in erytrocytes of patients with Parkinson`s disease]

[Article in Russian]
M G Makletsova  1 , G T Rikhireva  2 , V V Poleshuk  1 , K V Grjakalov  2 , S L Timerbaeva  1 , T N Fedorova  1
Affiliations

[The effect of antioxidants on in vivo and in vitro methemoglobin formation in erytrocytes of patients with Parkinson`s disease]

[Article in Russian]
M G Makletsova et al. Biomed Khim. 2016 Mar-Apr.

Abstract
in English, Russian

Methemoglobin formation was examined in erytrocytes of 16 patients with Parkinson`s disease (PD) (stage 3-4 by the Hoehn and Yahr scale). The patients receiving levodopa-containing drugs (madopar, nakom) were also treated with intramuscular injections of mexidol (daily dose 100 mg/day) for 14 days. Control group included 12 clinically healthy persons. The erythrocyte methemoglobin content was determined by electronic paramagnetic resonance (EPR) using the EPR signal intensity with g-factor 6.0. The methemoglobin content was significantly higher in erythrocytes of PD patients than in healthy donors. The complex therapy with mexidol normalized the methemoglobin content in erythrocytes of PD patients. Incubation in vitro of erythrocytes of donors and PD patients with acrolein increased the methemoglobin content, while incubation with carnosine normalized the methemoglobin content in erythrocytes of PD patients. Prophylactic (i.e. before acrolein addition) and therapeutic administration of carnosine to the incubation system with acrolein decreased the methemoglobin content to its initial level. Results of this study suggest that inclusion of the antioxidants mexidol and carnosine in the scheme of basic therapy of PD may reduce side effects associated with methemoglobinemia.

Issledovali 16 bol'nykh s bolezn'iu Parkinsona (BP, 3–4 stadii zabolevaniia po shkale Hoehn-Yahr). Patsienty, nakhodivshiesia na bazovom lechenii levodopa preparatami (madopar, nakom), v techenie 14 dneĭ poluchali meksidol v doze 100 mg/sutki (v/m). Kontrolem sluzhila gruppa iz 12 prakticheski zdorovykh lits. Opredelenie soderzhaniia metgemoglobina v éritrotsitakh provodili s pomoshch'iu metoda élektronnogo paramagnitnogo rezonansa (ÉPR) po intensivnosti signala ÉPR s g-faktorom v oblasti 6.0. V éritrotsitakh bol'nykh s BP vyiavleno znachitel'noe povyshenie soderzhaniia metgemoglobina po sravneniiu s donorami. Kompleksnaia terapiia s meksidolom normalizovala soderzhanie metgemoglobina v éritrotsitakh bol'nykh s BP. Inkubatsiia in vitro éritrotsitov donorov i patsientov s BP s akroleinom privodila k uvelicheniiu soderzhaniia metgemoglobina. Vvedenie karnozina v étikh usloviiakh normalizovalo soderzhanie metgemoglobina. “Profilakticheskoe” (do akroleina) i “terapevticheskoe” vvedenie karnozina v sredu inkubatsii éritrotsitov s akroleinom sposobstvovalo snizheniiu soderzhaniia metgemoglobina do iskhodnogo urovnia. Poluchennye dannye svidetel'stvuiut o tselesoobraznosti vkliucheniia antioksidantov (meksidola i karnozina) v bazovuiu terapiiu BP s tsel'iu snizheniia pobochnykh éffektov, sviazannykh s obrazovaniem metgemoglobina.

Keywords: Parkinson's disease; acrolein; antioxidants; carnosine; methemoglobin; mexidol.

PubMed Disclaimer

MeSH terms

Supplementary concepts

LinkOut - more resources